Clinical Trial Update: An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 open-label dose-escalation study evaluating the safety and tolerability of the anti-KIR antibody 1-7F9 in patients with multiple myeloma, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• 1-7F9 anti-KIR antibody (anti-KIR monoclonal antibody 1-7F9)

Snippet

Sponsor: Innate Pharma | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2012-06-28